Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

[1]  D. Medini,et al.  Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. , 2013, Vaccine.

[2]  R. Rappuoli,et al.  Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. , 2013, The Lancet. Infectious diseases.

[3]  John L. Perez,et al.  A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. , 2013, Vaccine.

[4]  T. Vesikari,et al.  Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials , 2013, The Lancet.

[5]  S. Halperin,et al.  The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada , 2013, The Pediatric infectious disease journal.

[6]  Monica Lahra,et al.  Annual report of the Australian Meningococcal Surveillance Programme, 2011. , 2012, Communicable diseases intelligence quarterly report.

[7]  John L. Perez,et al.  Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. , 2012, The Lancet. Infectious diseases.

[8]  L. Harrison,et al.  The changing and dynamic epidemiology of meningococcal disease. , 2012, Vaccine.

[9]  M. Valenzuela,et al.  Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study , 2012, The Lancet.

[10]  Ly-Mee Yu,et al.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. , 2012, JAMA.

[11]  M. Pizza,et al.  Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults , 2011, Human vaccines.

[12]  D. Toneatto,et al.  The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans , 2011, Human vaccines.

[13]  D. Lennon,et al.  Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers , 2011, Archives of Disease in Childhood.

[14]  A. Pollard,et al.  Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Rappuoli,et al.  Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines , 2010, Proceedings of the National Academy of Sciences.

[16]  R. Rappuoli,et al.  Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. , 2010, Vaccine.

[17]  M. A. Sáfadi,et al.  Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention , 2010, Neurological research.

[18]  J. van de Kassteele,et al.  Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. , 2009, Vaccine.

[19]  P. Stehr-Green,et al.  Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. , 2009, International journal of epidemiology.

[20]  Y. Galloway,et al.  Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. , 2009, The New Zealand medical journal.

[21]  K. Mulholland,et al.  Phase II meningococcal B vesicle vaccine trial in New Zealand infants , 2008, Archives of Disease in Childhood.

[22]  K. Rasanathan,et al.  Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens , 2007, Clinical and Vaccine Immunology.

[23]  K. Mulholland,et al.  New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 Months , 2007, The Pediatric infectious disease journal.

[24]  K. Mulholland,et al.  MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. , 2005, Vaccine.

[25]  R. Rappuoli,et al.  The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. , 2005, Vaccine.

[26]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[27]  Ying Zhang,et al.  Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein , 2004, Infection and Immunity.

[28]  E. Rosenqvist,et al.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. , 2003, Vaccine.

[29]  N. Andrews,et al.  Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. , 2001, Vaccine.

[30]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[31]  E. Rothstein,et al.  Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates. , 1999, Current medical research and opinion.

[32]  Annual report of the Australian Meningococcal Surveillance Programme 1996. , 1997, Communicable diseases intelligence.

[33]  M. H. Terry,et al.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. , 1991, NIPH annals.

[34]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.

[35]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.

[36]  C. Cordova,et al.  TYPE-III HYPERUPOPROTEINÆMIA , 1977, The Lancet.

[37]  D. Kasper,et al.  Immunologic response of man to group B meningococcal polysaccharide vaccines. , 1972, The Journal of infectious diseases.